Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Hospira Receives TGA Approval for Nivestim™, Australia’s First Biosimilar Filgrastim

September 26, 2010 By Bio-Medicine.Org

MELBOURNE, Australia, Sept. 26 /PRNewswire-FirstCall/ —
Hospira, Inc. (NYSE:
HSP
), the world leader in generic injectable pharmaceuticals,
today announced that it has received Australian Therapeutic Goods
Administration (TGA) approval for its biosimilar filgrastim
product, Nivestim™.

Nivestim has been approved for a range of indications, including
the prevention of febrile neutropenia (FN) and reduction in
duration of chemotherapy-induced neutropenia (CIN). Neutropenia is
the most serious hematological toxicity that occurs as a result of
cancer chemotherapy and can lead to chemotherapy dose reductions
and/or dose delays compared with the prescribed schedule.(1)

Nivestim is the first biosimilar version of Neupogen®
approved in Australia. Neupogen has current sales within Australia
of approximately AUD25 million (U.S. $24 million). Hospira is
working closely with Australian government agencies to ensure
efficient market access for biosimilars, and has submitted an
application to have Nivestim listed on the Australian
Pharmaceutical Benefits Scheme. Listing and product launch are
expected during the first half of 2011.

“Approval of Nivestim, the first biosimilar filgrastim in
Australia, is another important milestone for Hospira as we build
our global biosimilars portfolio,” said Tim Oldham, president, Asia
Pacific, Hospira. “Nivestim will help reduce the cost of providing
this lifesaving therapy across Australia, and includes a unique
combination of administration, storage and safety features that
will enhance safety for healthcare professionals and patients.”

Three pre-filled syringe presentations of Nivestim were approved
in Australia: 300 mcg/0.5 mL, 480 mcg/0.5 mL and a unique 120
mcg/0.2 mL low body weight presentation.

In a large, randomized Phase lll study, Nivestim demonstrated
comparable efficacy to Neupogen in the prevention o

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech